InventisBio's Oral TYK2 Inhibitor Hits Best-in-Class Bar in Psoriasis Phase III

China-based InventisBio has reported a registration-grade Phase III win for nomelcitinib (D-2570), a selective oral TYK2 inhibitor, in 391 patients with moderate to severe plaque psoriasis. At week 16, both active arms achieved PASI 90 response rates above 70% and PGA 0/1 rates above 80%, significantly outperforming placebo, with separation visible as early as week 4 and no new safety signals versus prior Phase II experience or other JH2-selective TYK2 agents, positioning the molecule as a potential best-in-class oral immunology asset.

The data look competitive against the current oral and injectable field. Disclosed comparators such as icotrokinra in the ICONIC programmes posted PASI 90 rates in the high-40s to high-50s and PGA 0/1 rates in the mid-60s to 70% range at week 16, so nomelcitinib's margins are materially wider. InventisBio is already running a head-to-head Phase III against Bristol Myers Squibb's deucravacitinib to formalise superiority.

Beyond psoriasis, the company is advancing Phase II studies in ulcerative colitis (UC), psoriatic arthritis, systemic lupus erythematosus (SLE) and vitiligo, plus a US Phase II psoriasis trial.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details